Biotechs With No Drugs in Trial Are Raising Millions in IPOs

Biotech IPOs are on track for a near-record year, with a crop of offerings that are younger, more highly valued—and some say riskier—than any in recent memory.

from WSJ.com: US Business https://ift.tt/2PznLkh
via IFTTT